Private subsidiary of BioTime offers 3 million shares at $1.00 apiece
By Devika Patel
Knoxville, Tenn., Aug. 24 - OncoCyte Corp. sold $3 million of stock in a private placement on Aug. 23, according to an 8-K filed Wednesday with the Securities and Exchange Commission.
The company sold 3 million common shares at $1.00 apiece to George Karfunkel.
Proceeds will be used to expand the company's development of novel proprietary diagnostics and therapeutics for cancer.
OncoCyte is a private subsidiary of BioTime, Inc., an Emeryville, Calif., biotechnology company that develops blood plasma volume expanders, blood replacement solutions for hypothermic surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment and other applications.
| Issuer: | OncoCyte Corp.
|
| Issue: | Common stock
|
| Amount: | $3 million
|
| Shares: | 3 million
|
| Price: | $1.00
|
| Warrants: | No
|
| Investor: | George Karfunkel
|
| Settlement date: | Aug. 23
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
